The article reviews the management of infusion-related reactions (IRRs) in cancer therapy, emphasizing the importance of standardized procedures to ensure patient safety and optimal outcomes. IRRs, which can range from mild to severe anaphylactic reactions, typically occur within minutes to hours after drug infusion. The authors highlight the need for careful monitoring at infusion initiation, prompt recognition, and appropriate clinical assessment of IRR severity, followed by immediate management. Standardization in prevention, management, and reporting of IRRs across institutions is crucial to address quality and safety gaps in cancer care. The article provides a comprehensive overview of the signs and symptoms of IRRs, risk factors, and strategies for prophylaxis and management. It also discusses the role of premedication, such as corticosteroids and antihistamines, in preventing and mitigating reactions. The management protocol includes interruption of infusion, administration of supportive medications, and careful monitoring until symptoms resolve. The article emphasizes the importance of patient education, training for healthcare providers, and the use of standardized protocols to ensure safe and effective treatment. Finally, it addresses the challenges and considerations in restarting treatment after an IRR episode, including the assessment of risk, clinical factors, and patient factors.The article reviews the management of infusion-related reactions (IRRs) in cancer therapy, emphasizing the importance of standardized procedures to ensure patient safety and optimal outcomes. IRRs, which can range from mild to severe anaphylactic reactions, typically occur within minutes to hours after drug infusion. The authors highlight the need for careful monitoring at infusion initiation, prompt recognition, and appropriate clinical assessment of IRR severity, followed by immediate management. Standardization in prevention, management, and reporting of IRRs across institutions is crucial to address quality and safety gaps in cancer care. The article provides a comprehensive overview of the signs and symptoms of IRRs, risk factors, and strategies for prophylaxis and management. It also discusses the role of premedication, such as corticosteroids and antihistamines, in preventing and mitigating reactions. The management protocol includes interruption of infusion, administration of supportive medications, and careful monitoring until symptoms resolve. The article emphasizes the importance of patient education, training for healthcare providers, and the use of standardized protocols to ensure safe and effective treatment. Finally, it addresses the challenges and considerations in restarting treatment after an IRR episode, including the assessment of risk, clinical factors, and patient factors.